![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BEND2 |
Gene summary for BEND2 |
![]() |
Gene information | Species | Human | Gene symbol | BEND2 | Gene ID | 139105 |
Gene name | BEN domain containing 2 | |
Gene Alias | CXorf20 | |
Cytomap | Xp22.13 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q8NDZ0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
139105 | BEND2 | HCC1 | Human | Liver | HCC | 5.28e-09 | 9.35e-01 | 0.5336 |
139105 | BEND2 | HCC2 | Human | Liver | HCC | 3.26e-08 | 7.22e-01 | 0.5341 |
139105 | BEND2 | HCC5 | Human | Liver | HCC | 1.54e-03 | 4.15e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | ![]() |
Skin | AK | ![]() |
Skin | SCCIS | ![]() |
Skin | cSCC | ![]() |
Thyroid | HT | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BEND2 | SNV | Missense_Mutation | rs759938608 | c.1357N>T | p.Arg453Cys | p.R453C | Q8NDZ0 | protein_coding | tolerated(0.18) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
BEND2 | SNV | Missense_Mutation | rs377313223 | c.755N>G | p.Asn252Ser | p.N252S | Q8NDZ0 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-AC-A2FE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
BEND2 | SNV | Missense_Mutation | c.2066N>T | p.Ser689Leu | p.S689L | Q8NDZ0 | protein_coding | deleterious(0.04) | probably_damaging(0.971) | TCGA-AO-A0J7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
BEND2 | SNV | Missense_Mutation | c.118N>T | p.Asn40Tyr | p.N40Y | Q8NDZ0 | protein_coding | deleterious_low_confidence(0.03) | benign(0.012) | TCGA-C8-A1HF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
BEND2 | SNV | Missense_Mutation | c.2038N>T | p.Ala680Ser | p.A680S | Q8NDZ0 | protein_coding | deleterious(0.01) | probably_damaging(0.976) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
BEND2 | SNV | Missense_Mutation | c.722N>G | p.Ala241Gly | p.A241G | Q8NDZ0 | protein_coding | tolerated(0.14) | possibly_damaging(0.665) | TCGA-GI-A2C8-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Adriamycin | SD | |
BEND2 | insertion | Nonsense_Mutation | novel | c.1352_1353insTGAGGATAGGTTTTAGGTGATATTCAGAACCATGACTA | p.Met451IlefsTer6 | p.M451Ifs*6 | Q8NDZ0 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
BEND2 | SNV | Missense_Mutation | novel | c.1679N>G | p.Lys560Arg | p.K560R | Q8NDZ0 | protein_coding | tolerated(0.23) | benign(0.332) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
BEND2 | SNV | Missense_Mutation | c.2302N>C | p.Ala768Pro | p.A768P | Q8NDZ0 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-DS-A0VN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
BEND2 | SNV | Missense_Mutation | rs778717370 | c.2056N>A | p.Ala686Thr | p.A686T | Q8NDZ0 | protein_coding | deleterious(0.01) | benign(0.186) | TCGA-A6-2680-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |